B

Bioventus Inc
NASDAQ:BVS

Watchlist Manager
Bioventus Inc
NASDAQ:BVS
Watchlist
Price: 7.21 USD -3.09% Market Closed
Market Cap: 596.7m USD

During the last 3 months Bioventus Inc insiders have not bought any shares, and sold 206.9k USD worth of shares. The stock price has increased by 6% over this period (open performance analysis).

The last transaction was made on Dec 4, 2025 by Nohra Guy P , who sold 75.7k USD worth of BVS shares.

Last Transactions:
Nohra Guy P
$-75.7k
Mcmurry-Heath Michelle
$-131.3k
D'adamio Anthony
$-22.4k
Singleton Mark Leonard
$-29.3k
Church Katrina J
$-9.7k
Singleton Mark Leonard
$-53.6k
D'adamio Anthony
$-25.5k
Church Katrina J
$-9.9k
Church Katrina J
$-15.7k
Singleton Mark Leonard
$-66.2k
D'adamio Anthony
$-44.6k
Claypoole Robert E
$-262k
D'adamio Anthony
$-61.6k
Singleton Mark Leonard
$-113k
Church Katrina J
$-26.7k
Bartholdson John A.
$+218k
Bartholdson John A.
$+683.7k
Church Katrina J
$-14.3k
D'adamio Anthony
$-32.9k
Singleton Mark Leonard
$-51.3k
Singleton Mark Leonard
$-80.3k
D'adamio Anthony
$-66k
Church Katrina J
$-51.2k
Singleton Mark Leonard
$-19k
D'adamio Anthony
$-14.5k
Church Katrina J
$-6.3k
Singleton Mark Leonard
$-29.9k
D'adamio Anthony
$-17.1k
Church Katrina J
$-6.6k
Bihl Anthony P Iii
$+55k
Bartholdson John A.
$+71.8k
Michas Alexis P
$+71.8k
View All Transactions

During the last 3 months Bioventus Inc insiders have not bought any shares, and sold 206.9k USD worth of shares. The stock price has increased by 6% over this period (open performance analysis).

The last transaction was made on Dec 4, 2025 by Nohra Guy P , who sold 75.7k USD worth of BVS shares.

Sold
0-3
months
206.9k USD
2
3-6
months
0 USD
0
6-9
months
61.4k USD
3
9-12
months
477.5k USD
4
Bought
0-3
months
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD

Bioventus Inc
Insider Trading Chart

Bioventus Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Bioventus Inc
Last Insider Transactions

Global
Insiders Monitor

Bioventus Inc
Glance View

Market Cap
596.7m USD
Industry
Health Care

Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.

BVS Intrinsic Value
14.81 USD
Undervaluation 51%
Intrinsic Value
Price
B

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top